ArticleBiomaterials and biosystems2024
Enhanced osteogenic potential of spider silk fibroin-based composite scaffolds incorporating carboxymethyl cellulose for bone tissue engineering.
Article in Biomaterials and biosystems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Biomimetic Three-Dimensional (3D) Scaffolds from Sustainable Biomaterials: Innovative Green Medicine Approach to Bone Regeneration.Journal of functional biomaterials · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the characteristics of composite scaffolds that combine fibroin derived from spider silk and carboxymethyl cellulose (CMC) in the field of bone tissue engineering. Fibroin, obtained from spider silk, serves as a valuable biomaterial and constitutes the primary component of fibrous protein-based spider silk threads. To enhance the binding efficiency in bone formation after scaffold implantation, CMC was integrated into fibroin, aiming to improve the injectability properties of the scaffold in bone substitutes. For bone marrow mesenchymal stem cell (BMSC) tissue engineering, BMSCs isolated from mice were seeded onto the scaffold, and the rate of cell proliferation was assessed. The composite scaffold, with the addition of CMC to fibroin, exhibited superior characteristics compared to scaffolds containing only silks, including porous morphology, porosity, surface wettability, water absorption, and thermal properties. Alkaline phosphatase activity in BMSCs was significantly higher in the CMC-containing scaffold compared to the silk-only scaffold, and the CMC-containing scaffold demonstrated increased expression of osteocyte marker genes and proteins. In conclusion, the biocompatibility and hydrophilicity of CMC-containing scaffolds play essential roles in the growth and proliferation of osteocytes. Furthermore, the CMC-containing scaffold design proposed in this study is expected to have a substantial impact on promoting ossification of BMSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.